- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05889013
Utility of PCD Diagnostics to Improve Clinical Care
September 28, 2023 updated by: Connecticut Children's Medical Center
A Clinical Study to Gather Data on the Utility of Tests That Are Used to Make a Diagnosis of Primary Ciliary Dyskinesia (PCD)
This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD).
There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity.
Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice.
The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an observational study to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD).
Participant selection will be on a referral basis for the consideration of a clinical suspicion for PCD.
Participants will be identified by pulmonary providers that consider testing for PCD based on the clinical symptoms of the participant.
These providers will then refer for enrollment in the study based on the clinical considerations for a diagnosis of PCD.
Participants will be consented during the time of testing at the Pulmonary department.
Any patient referred by a clinician for concerns for PCD, including those who have had PCD genetics sent, or a ciliary biopsy performed will be enrolled in the study.
In addition, any participant who is referred for nasal nitric oxide testing and meets the inclusion and exclusion criteria for this testing, will also need to provide informed consent and be enrolled in the Nasal NO REDCap registry.
This equipment is not currently FDA approved or CLIA certified for PCD diagnostic testing and therefore referring clinicians will be informed that the results of this test should not influence clinical decision making regarding the diagnosis of PCD.
However, there is growing evidence that this testing has utility as a non-invasive screening tool for PCD and continued data from the general pediatric pulmonary population is needed.
Study Type
Observational
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Melanie S Collins, MD
- Phone Number: 860-545-9440
- Email: mcollin@connecticutchildrens.org
Study Contact Backup
- Name: Sigrid M Almeida, BS
- Phone Number: 8608375343
- Email: salmeida@connecticutchildrens.org
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06111
- Recruiting
- Pulmonary Division
-
Contact:
- Melanie S Collins, MD
- Phone Number: 860-545-9440
- Email: mcollin@connecticutchildrens.org
-
Contact:
- Sigrid M Almeida, BS
- Phone Number: 8608375343
- Email: salmeida@connecticutchildrens.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The target population are ages 2 and up.
Participant selection will be on a referral basis for the consideration of a clinical suspicion for PCD.
Participants will be identified by pulmonary providers that consider testing for PCD based on the clinical symptoms of the participant.
These providers will thenrefer for enrollment in the study based on the clinical considerations for a diagnosis of PCD.
Description
Inclusion Criteria:
- Age ≥ 2 years of age
- Must have two of the following clinical history points:
- Neonatal respiratory distress
- Chronic nasal congestion/runny nose
- Chronic cough
- Situs/laterality defects
- Bronchiectasis
- Ability to provide informed consent or consent of parent/guardian and ass
Exclusion Criteria:
- Recent history of sinus surgery or bloody nose in the past week
- Age < 2 years of age
- Inability to tolerate probe in nose
- Sinusitis or other respiratory exacerbation currently being treated with antibiotics
- Admitted to hospital for respiratory exacerbation (inpatient status)
- Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by the IRB)
- Any other reason for which the study investigators feel the patient is not a good candidate to complete the testing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Nasal Nitric Oxide
Participants who are referred by his/her clinician for nasal NO testing and meet the inclusion and exclusion criteria will undergo testing.
Clinical information regarding prior diagnostic testing will be collected at time of enrollment.
Participants that have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry
|
Collection of already performed clinical data and nNO testing
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Creation of Nasal NO REDCap registry
Time Frame: 2-3 years
|
To establish a research registry to characterize the features of individuals that undergo PCD diagnostic testing at Connecticut Children's Medical Center and UCONN.
|
2-3 years
|
Evaluation of utility of PCD diagnostic testing
Time Frame: 2-3 years
|
To evaluate the utility of PCD diagnostic testing, including potential use of nasal nitric oxide in comparison to genetic testing and ciliary biopsy, in pulmonary practice at Connecticut Children's Medical Center and UCONN.
|
2-3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Refinement and Improvement of PCD Diagnostic Testing
Time Frame: 1-2 years
|
To refine and improve current diagnostic processes for PCD diagnosis at CCMC using information gathered from the research registry established through Primary aims 1 and 2.
|
1-2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Melanie S Collins, MD, Connecticut Children's Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 27, 2023
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
May 25, 2023
First Submitted That Met QC Criteria
June 2, 2023
First Posted (Actual)
June 5, 2023
Study Record Updates
Last Update Posted (Actual)
October 2, 2023
Last Update Submitted That Met QC Criteria
September 28, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neurologic Manifestations
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Otorhinolaryngologic Diseases
- Movement Disorders
- Abnormalities, Multiple
- Ciliopathies
- Dyskinesias
- Ciliary Motility Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Antioxidants
- Free Radical Scavengers
- Endothelium-Dependent Relaxing Factors
- Gasotransmitters
- Nitric Oxide
Other Study ID Numbers
- 23-052
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Ciliary Dyskinesia
-
University Hospital MuensterAssistance Publique - Hôpitaux de Paris; University of Pisa; Medical University... and other collaboratorsRecruitingPrimary Ciliary Dyskinesia (PCD)Germany
-
University of Alabama at BirminghamMassachusetts General HospitalRecruitingCovid19 | Sinusitis | Cystic Fibrosis | COPD | PCD - Primary Ciliary DyskinesiaUnited States
-
University Hospital MuensterUniversity of Pisa; Medical University of Vienna; Hacettepe University; Charite... and other collaboratorsRecruitingPrimary Ciliary Dyskinesia | Ciliary Motility DisordersGermany
-
The University of Texas Health Science Center,...RecruitingPrimary Ciliary DyskinesiaUnited States
-
Vanderbilt University Medical CenterRecruiting
-
The Hospital for Sick ChildrenProvincial Health Services AuthorityCompletedPrimary Ciliary DyskinesiaCanada
-
University of AlbertaCompleted
-
Gazi UniversityCompletedPrimary Ciliary DyskinesiaTurkey
-
ReCode TherapeuticsSano Genetics; ReverbaRecruitingPrimary Ciliary DyskinesiaUnited States
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPrimary Ciliary DyskinesiaUnited States
Clinical Trials on Nasal Nitric Oxide testing
-
New York Medical CollegeRecruitingHyperventilation | Postural Orthostatic Tachycardia Syndrome | HypocapniaUnited States
-
Ascensia Diabetes CareCompleted
-
Sanotize Research and Development corp.RecruitingRecurrent Acute RhinosinusitisCanada
-
Beyond Air Inc.Recruiting
-
Tomsk National Research Medical Center of the Russian...Siberian State Medical UniversityCompletedCoronavirus Infection | Pneumonia, Viral | HypoxemiaRussian Federation
-
Imperial College LondonGlaxoSmithKlineWithdrawnHealthy Smokers | Healthy Non-smokers | Patients With Mild Asthma | Patints With COPD (GOLD II)United Kingdom
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
University of Michigan Rogel Cancer CenterCompletedBrain NeoplasmsUnited States
-
BellerophonCompletedChronic Obstructive Pulmonary Disease | Idiopathic Pulmonary Fibrosis | Pulmonary HypertensionBelgium
-
Beth Israel Deaconess Medical CenterBoston Children's HospitalCompletedPrimary Sclerosing Cholangitis | Inflammatory Bowel DiseaseUnited States